

Puja mehta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2136031/publications.pdf>

Version: 2024-02-01

45
papers

9,321
citations

393982

19
h-index

288905

40
g-index

47
all docs

47
docs citations

47
times ranked

21726
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19: consider cytokine storm syndromes and immunosuppression. <i>Lancet, The</i> , 2020, 395, 1033-1034.	6.3	7,677
2	COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e594-e602.	2.2	200
3	Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. <i>Lancet Rheumatology, The</i> , 2020, 2, e358-e367.	2.2	197
4	Local and systemic responses to SARS-CoV-2 infection in children and adults. <i>Nature</i> , 2022, 602, 321-327.	13.7	179
5	The intersection of COVID-19 and autoimmunity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	138
6	Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. <i>Lancet Respiratory Medicine, the</i> , 2020, 8, 822-830.	5.2	110
7	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.5	89
8	In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. <i>Blood</i> , 2008, 111, 2378-2381.	0.6	85
9	B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?. <i>Lancet Rheumatology, The</i> , 2020, 2, e589-e590.	2.2	62
10	Post-COVID-19 assessment in a specialist clinical service: a 12-month, single-centre, prospective study in 1325 individuals. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001041.	1.2	57
11	SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience. <i>Rheumatology</i> , 2010, 49, 823-824.	0.9	53
12	Is fibromyalgia associated with a unique cytokine profile? A systematic review and meta-analysis. <i>Rheumatology</i> , 2021, 60, 2602-2614.	0.9	53
13	Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. <i>Current Opinion in Rheumatology</i> , 2021, 33, 419-430.	2.0	53
14	JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. <i>European Respiratory Journal</i> , 2020, 56, 2001919.	3.1	52
15	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e855-e864.	2.2	38
16	Thrombosis and Behcet's syndrome in non-endemic regions. <i>Rheumatology</i> , 2010, 49, 2003-2004.	0.9	37
17	Avascular necrosis in HIV. <i>Rheumatology International</i> , 2013, 33, 235-238.	1.5	28
18	Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 912.	4.6	28

#	ARTICLE	IF	CITATIONS
19	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2021, 48, 1053-1059.	1.0	22
20	Novel compound heterozygous mutations in ENPP1 cause hypophosphataemic rickets with anterior spinal ligament ossification. <i>Rheumatology</i> , 2012, 51, 1919-1921.	0.9	20
21	What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?. <i>Frontiers in Immunology</i> , 2020, 11, 589.	2.2	18
22	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology, The</i> , 2021, 3, e71-e82.	2.2	18
23	Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis. <i>Lancet Rheumatology, The</i> , 2021, 3, e171-e172.	2.2	14
24	Difficult case: rituximab in anti-SRP antibody myositis in pregnancy. <i>Practical Neurology</i> , 2019, 19, 444-446.	0.5	9
25	Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. <i>Lancet Rheumatology, The</i> , 2021, 3, e9-e10.	2.2	9
26	The Rapunzel syndrome: is it an Asian problem? (case report and review of literature). <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 937-940.	0.8	8
27	Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe?. <i>Lancet Rheumatology, The</i> , 2021, 3, e394-e395.	2.2	8
28	Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice. <i>Lancet Rheumatology, The</i> , 2021, 3, e92-e94.	2.2	7
29	Management of interstitial lung disease (ILD) in myositis syndromes: A practical guide for clinicians. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101769.	1.4	7
30	Steroid-resistant remitting seronegative symmetrical synovitis with pitting oedema associated with gout treated with etanercept. <i>Rheumatology</i> , 2014, 53, 1908-1910.	0.9	6
31	Intravenous anakinra for cytokine storm syndromes – Authors' reply. <i>Lancet Rheumatology, The</i> , 2020, 2, e522-e523.	2.2	5
32	Targeting hyperinflammation in infection: can we harness the COVID-19 therapeutics momentum to end the dengue drugs drought?. <i>Lancet Microbe, The</i> , 2021, 2, e277-e278.	3.4	5
33	Can we finally exonerate methotrexate as a factor in causing or exacerbating fibrotic interstitial lung disease in patients with rheumatoid arthritis?. <i>Clinical Rheumatology</i> , 2022, 41, 2925-2928.	1.0	4
34	Lateral medullary syndrome with anti-neuronal antibodies (anti-Ta/Ma2) in primary Sjogren's syndrome. <i>Rheumatology</i> , 2009, 48, 1174-1176.	0.9	3
35	A late presentation of Loews-Dietz syndrome: joint hypermobility is not always benign. <i>Rheumatology</i> , 2014, 53, 574-576.	0.9	3
36	Aetiopathology of rheumatoid arthritis. <i>Medicine</i> , 2010, 38, 163-166.	0.2	2

#	ARTICLE	IF	CITATIONS
37	Painful myositis in the anti-synthetase syndrome with anti-PL12 antibodies. Rheumatology International, 2012, 32, 825-827.	1.5	2
38	Dr. Conway et al reply. Journal of Rheumatology, 2021, , jrheum.210913.	1.0	2
39	Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?. Mediterranean Journal of Rheumatology, 2020, 31, 112.	0.3	2
40	Rheumatologists have an important role in the management of interstitial lung disease (ILD): a cross-speciality, multi-centre, U.K. perspective. Rheumatology, 2022, , .	0.9	1
41	Self-perceived disease activity was the strongest predictor of COVID-19 pandemic-related concerns in young people with autoimmune rheumatic diseases, irrespective of their gender, with females reporting higher concerns. Rheumatology Advances in Practice, 2022, 6, rkac031.	0.3	1
42	P118â€fOrthopaedic surgical interventions in a cohort of patients with hypermobility related disorders, compared with chronic pain syndrome patients in a tertiary referral centre. Rheumatology, 2020, 59, .	0.9	0
43	P124â€fAre chronic pain syndromes associated with a unique cytokine profile? A systematic review and meta-analysis. Rheumatology, 2021, 60, .	0.9	0
44	Central sensitisation: causes, therapies, and terminology. Lancet Rheumatology, The, 2021, 3, e546-e547.	2.2	0
45	Dr. Conway et al reply. Journal of Rheumatology, 2022, 49, 120.2-121.	1.0	0